MyFinsight
Home
Blog
About
Proceeds from the
issuance of common stock
$6,672K
Proceeds from exercise of
stock options
$8K
Net cash, cash
equivalents, and restricted...
$6,240K
(-36.88%↓ Y/Y)
Canceled cashflow
$440K
Net increase
(decrease) in cash, cash...
$4,424K
(180.20%↑ Y/Y)
Canceled cashflow
$1,816K
Equity financing costs
$275K
Other
-$153K
(60.57%↑ Y/Y)
Payment of debt issuance
costs
$11K
(-59.26%↓ Y/Y)
Repayment of term loan and
notes payable
$1K
(-91.67%↓ Y/Y)
Depreciation and
amortization
$1,387K
(-51.77%↓ Y/Y)
Other current assets
-$1,379K
(-333.65%↓ Y/Y)
Other long-term
assets
-$1,020K
(-20500.00%↓ Y/Y)
Share-based compensation
expense
$820K
(-59.22%↓ Y/Y)
Accounts payable and
other accrued...
$767K
(92.23%↑ Y/Y)
Accrued interest,
amortization of debt issuance...
$329K
(-48.51%↓ Y/Y)
Accounts receivable
-$294K
(72.90%↑ Y/Y)
Provision for credit
losses
$92K
(-15.60%↓ Y/Y)
Reduction (accretion) of
lease right-of-use...
$24K
Impairment loss on
intangible assets
$12K
(-87.88%↓ Y/Y)
Inventory excess and
obsolescence
$6K
(-45.45%↓ Y/Y)
Net cash, cash
equivalents, and restricted...
-$1,562K
(89.70%↑ Y/Y)
Net cash, cash
equivalents, and restricted...
-$254K
(-9.48%↓ Y/Y)
Canceled cashflow
$6,130K
Revenues
$26,861K
Net loss
-$7,273K
(67.77%↑ Y/Y)
Purchase of property and
equipment
$197K
(57.60%↑ Y/Y)
Patent costs and
intangible asset...
$57K
(-46.73%↓ Y/Y)
Canceled cashflow
$26,861K
Current and long-term
operating lease...
-$372K
(-48.80%↓ Y/Y)
Deferred revenue
-$47K
(58.77%↑ Y/Y)
Employee related
expenses (less...
$19,420K
Direct costs and
expenses (less employee...
$3,540K
Sales and marketing
education and event...
$2,235K
Interest expense
$1,982K
Other segment items
$1,893K
Contracted services
expenses
$1,692K
Depreciation and
amortization expense
$1,387K
(-51.77%↓ Y/Y)
Occupancy and equipment
service expenses
$974K
Share-based compensation
expenses
$820K
Clinical trials and
associated costs
$191K
Back
Back
Cash Flow
BIODESIX INC (BDSX)
BIODESIX INC (BDSX)
source: myfinsight.com